c-Jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1153-1160

  Mikami, Takashi ^a,b   Koyama, Takaaki ^a,b   Koyama, Takashi ^b   Imakiire, Atsuhiro ^b   Yamamoto, Kengo ^b   Furuhata, Masae ^a   Toyota, Hiroko ^a   Mizuguchi, Junichiro ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis; Chemotherapeutic drug; JNK; Sarcoma; TRAIL

Indexed keywords

CISPLATIN; DNA; DOXORUBICIN; LIPOCORTIN 5; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; SARCOMA CELL; STAINING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 8; CASPASES; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DOXORUBICIN; ENZYME ACTIVATION; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MEMBRANE GLYCOPROTEINS; MEMBRANE POTENTIALS; MITOCHONDRIAL MEMBRANES; SARCOMA; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645822782     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Bramwell VH: Osteosarcomas and other cancers of bone. Curr Opin Oncol 12: 330-336, 2000.
2. Eilber FR and Rosen G: Adjuvant chemotherapy for osteosarcoma. Semin Oncol 16: 312-322, 1989.
3. Colvin OM: Drug resistance in the treatment of sarcomas. Semin Oncol 24: 580-591, 1997.
4. Trieb K and Kotz R: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 33: 11-17, 2001.
5. Reed JC: Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 11: 68-75, 1999.
6. Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
7. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419, 1998.
8. Reed JC: Bcl-2 family proteins. Oncogene 77: 3225-3236, 1998.
9. Susin SA, Zamzami N and Kroemer G: Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta 1366: 151-165, 1998.
10. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001.
11. Rincon M, Flavell RA and Davis RA: The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Rad Biol Med 28: 1328-1337, 2000.
12. Takada E, Shimo K, Hata K, Abiake M, Mukai Y, Moriyama M, Heasley L and Mizuguchi J: Interferon-beta-induced activation of c-Jun NH(2)-terminal kinase mediates apoptosis through up-regulation of CD95 in CH31 B lymphoma cells. Exp Cell Res 304: 518-530, 2005.
13. Takada E, Toyota H, Suzuki J and Mizuguchi J: Prevention of anti-IgM-induced apoptosis accompanying G1 arrest in B lymphoma cells overexpressing dominant-negative mutant form of c-Jun N-terminal kinase 1. J Immunol 166: 1641-1649, 2001.
14. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
15. Chen YR and Tan TH: The c-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol 16: 651-662, 2000.
16. Reed JC and Kroemer G: Mechanisms of mitochondrial membrane permeabilization. Cell Death Differ 7: 1145, 2000.
17. Itoh M, Noutomi T, Toyota H and Mizuguchi J: Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Oral Oncol 39: 269-276, 2003.
18. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741, 1999.
19. Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M and Mizuguchi J: Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthopaed Res 21: 949-957, 2003.
20. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R and Zhou T: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22: 2034-2044, 2003.
21. Vivo C, Liu W and Broaddus VC: c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 278: 25461-25467, 2003.
22. Srivastava RK: TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546, 2001.
23. Walczak H and Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256: 58-66, 2000.
24. Chandar N, Billig B, McMaster J and Novak J: Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65: 208-214, 1992.
25. Suzuki H, Hotta T, Koyama T, Komagata M, Imakiire A, Yanase N, Yoshimoto T and Mizuguchi J: Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents cooperatively induce apoptotic cell death in both sarcoma and myeloma cells. Anticancer Res 23: 3247-3253, 2003.
26. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST and van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415-1420, 1994.
27. Niitani H and Kobayashi K: Cisplatin/carboplatin therapy in non-small cell lung cancer. Oncology 49 Suppl 1: 51-56, 1992.
28. Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43, 2001.
29. Osborn MT and Chambers TC: Role of the stress-activated/ c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem 271: 30950-30955, 1996.
30. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278: 19245-19256, 2003.
31. Cantarella G, Risuglia N, Lombardo G, Lempereur L, Nicoletti F, Memo M and Bernardini R: Protective effects of estradiol on TRAIL-induced apoptosis in a human oligodendrocytic cell line: evidence for multiple sites of interactions. Cell Death Differ 11: 503-511, 2004.
32. Yanase N, Hata K, Shimo K, Hayashida M, Evers BM and Mizuguchi J: Requirement of c-Jun NH(2)-terminal kinase activation in interferon-alpha- induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res 310: 10-21, 2005.
33. Bain J, McLauchlan H, Elliott M and Cohen P: The specificities of protein kinase inhibitors: an update. Biochem J 371: 199-204, 2003.
34. Bogoyevitch MA, Boehm I, Oakley A, Ketterman AJ and Barr RK: Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 1697: 89-101, 2004.
35. Yu R, Shtil AA, Tan TH, Roninson IB and Kong AN: Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. Cancer Lett 107: 73-81, 1996.
36. Sanchez-Perez I, Murguia JR and Perona R: Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16: 533-540, 1998.
37. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR and Sun SY: c-Jun NH2-terminal kinase-mediated upregulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 64: 7570-7578, 2004.
38. Hersey P and Zhang XD: How melanoma cells evade trail-induced apoptosis. Nature Rev Cancer 1: 142-150, 2001.
39. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH and Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17: 1675-1687, 1998.
40. Kim Y, Suh N, Sporn M and Reed JC: An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 277: 22320-22329, 2002.
41. Fuchs SY, Adler V, Pincus MR and Ronai Z: MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95: 10541-10546, 1998.
42. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV and Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703, 1991.